StreetInsider.com News Articles

Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 20 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260720/26789905.html

Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 20 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260720/26789905.html

Agenus (AGEN) files for 2.13M share offering by selling stockholders

Mon, 20 Jul 2026 06:08:11 -0400

Agenus (NASDAQ: AGEN) has filed for up to 2,133,333 share offering by selling stockholders.

Agenus (AGEN) files for 2.13M share offering by selling stockholders

Mon, 20 Jul 2026 06:08:11 -0400

Agenus (NASDAQ: AGEN) has filed for up to 2,133,333 share offering by selling stockholders.

Form S-3 AGENUS INC

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786495.html

Form S-3 AGENUS INC

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786495.html

Form SCHEDULE 13G AGENUS INC Filed by: Invus Global Management, LLC

Fri, 17 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260717/26784813.html

Form SCHEDULE 13G AGENUS INC Filed by: Invus Global Management, LLC

Fri, 17 Jul 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260717/26784813.html

Agenus to present BOT+BAL cancer data at ESMO 2026 congress

Fri, 17 Jul 2026 10:28:24 -0400

Agenus Inc. (Nasdaq: AGEN) announced that three abstracts from investigator-sponsored trials evaluating its drug combination botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23-27 in Madrid, Spain.

The three presentations cover neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcoma.

The first poster, from the NEOASIS study, will present updated data on neoadjuvant BOT+BAL use in mismatch repair-deficient (dMMR) colorectal cancer. It is scheduled for October 25 and will be presented by Emma Van Den Berg, MD, of the Netherlands Cancer Institute in Amsterdam.

The second poster

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Fri, 17 Jul 2026 10:28:00 -0400

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The studies span neoadjuvant colorectal cancer, refractory metastatic colorectal cancer and advanced sarcoma, reflecting continued investigator interest in BOT+BAL across distinct disease settings and tumor types.

The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. While biologically

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Fri, 17 Jul 2026 10:28:00 -0400

The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. While biologically

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Fri, 17 Jul 2026 10:28:00 -0400

The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. While biologically

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Fri, 17 Jul 2026 10:28:00 -0400

The NEOASIS poster will present updated data from a neoadjuvant cohort in mismatch repair-deficient (dMMR) colorectal cancer. While biologically

Form 4 AGENUS INC For: Jul 10 Filed by: ARMEN GARO H

Tue, 14 Jul 2026 15:30:00 -0400

si-local-file:///var/storage/secattach/20260714/26767967.html

Form 4 AGENUS INC For: Jul 10 Filed by: ARMEN GARO H

Tue, 14 Jul 2026 15:30:00 -0400

si-local-file:///var/storage/secattach/20260714/26767967.html

Agenus Inc. (AGEN) PT Raised to $30 at H.C. Wainwright

Mon, 13 Jul 2026 12:16:43 -0400

H.C. Wainwright analyst Emily Bodnar raised the price target on Agenus Inc. (NASDAQ: AGEN) to $30.00 (from $23.00) while maintaining a Buy rating.

The analyst comments "Model update based on shift in strategy and private placement; adjusting PT to $30. We have updated our model to reflect the company's shift in development of bot/bal to neoadjuvant MSS-CRC from metastatic MSS-CRC, previously. We now assume revenue for Stage 2 high-risk and Stage 3 patients, based on eligibility for the Phase 3 ROBBIN trial. We are assuming a launch in 2030 based on potential approval from the 2029 interim analysis on 75% of

Agenus Inc. (AGEN) PT Raised to $30 at H.C. Wainwright

Mon, 13 Jul 2026 12:16:43 -0400

H.C. Wainwright analyst Emily Bodnar raised the price target on Agenus Inc. (NASDAQ: AGEN) to $30.00 (from $23.00) while maintaining a Buy rating.

Agenus rises premarket; Micron, Western Digital slide

Mon, 13 Jul 2026 06:33:47 -0400

Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space.

Semiconductor stocks came under broad pressure after a steep decline in South Korean memory-chip makers spilled over into U.S.-listed peers, while biotech names gained on fresh financing announcements.

S&P 500 Futures fell 0.25% by 05:45 ET. Nasdaq 100 Futures slid 0.9%, while Dow Jones Futures inched 0.12%.

Here are some of the biggest premarket U.S. stock movers today:

Agenus surged 13% after the biotechnology company announced an $85 million private placement led by Commodore Capital, with participation from several life sciences investors. The

Agenus rises premarket; Micron, Western Digital slide

Mon, 13 Jul 2026 06:33:47 -0400

Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space.

S&P 500 Futures fell 0.25% by 05:45 ET. Nasdaq 100 Futures slid 0.9%, while Dow Jones Futures inched 0.12%.

Here are some of the biggest premarket U.S. stock movers today:

Agenus surged 13% after the biotechnology company announced an $85 million private placement led by Commodore Capital, with participation from several life sciences investors. The

Agenus rises premarket; Micron, Western Digital slide

Mon, 13 Jul 2026 06:33:47 -0400

Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space.

S&P 500 Futures fell 0.25% by 05:45 ET. Nasdaq 100 Futures slid 0.9%, while Dow Jones Futures inched 0.12%.

Here are some of the biggest premarket U.S. stock movers today:

Agenus surged 13% after the biotechnology company announced an $85 million private placement led by Commodore Capital, with participation from several life sciences investors. The

Form 8-K AGENUS INC For: Jul 13

Mon, 13 Jul 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260713/26759346.html

Form 8-K AGENUS INC For: Jul 13

Mon, 13 Jul 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260713/26759346.html

Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial

Mon, 13 Jul 2026 06:00:24 -0400

Agenus Inc. (Nasdaq: AGEN) has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, with up to an additional $255 million available upon full exercise of accompanying purchase warrants, for a combined total of up to $340 million.

The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The placement is expected to close on or about July 15, 2026, subject to customary closing conditions.

Proceeds are intended to fund the ROBBIN trial, a planned randomized global Phase 3 study evaluating neoadjuvant botensilimab and balstilimab

Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial

Mon, 13 Jul 2026 06:00:24 -0400

Proceeds are intended to fund the ROBBIN trial, a planned randomized global Phase 3 study evaluating neoadjuvant botensilimab and balstilimab

Agenus raises up to $340M to fund MSS colon cancer Phase 3 trial

Mon, 13 Jul 2026 06:00:24 -0400

Proceeds are intended to fund the ROBBIN trial, a planned randomized global Phase 3 study evaluating neoadjuvant botensilimab and balstilimab